Marc Duey - 10 Dec 2025 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Reporting relationship: Director
Issuer ticker: APRE
Reported as of: 10 Dec 2025
Net transaction value: +$25,000
SEC form: 4
Accepted by SEC: 11 Dec 2025, 08:31:55 UTC
Prior SEC filing: 09 Jun 2025
Next SEC filing: 17 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ John P. Hamill, as Attorney-in-Fact

Key filing fact

Marc Duey filed Form 4 for Aprea Therapeutics, Inc. (APRE) on 11 Dec 2025.

Key facts

This page summarizes Marc Duey's Form 4 filing for Aprea Therapeutics, Inc. (APRE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Dec 2025, 08:31.

Change

Previous filing in this sequence was filed on 09 Jun 2025.
Current net transaction value: +$25,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001925150 Primary reporting owner

Duey Marc

Relationship: Director
Address: 3805 OLD EASTON ROAD, DOYLESTOWN
Signature: /s/ John P. Hamill, as Attorney-in-Fact
Signature date: 11 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APRE transaction

Common Stock

Purchase

Transaction value: $25,000
Shares: +21,459
Change %: +9.1%
Price: $1.16
Shares after: 256,155
Date: 10 Dec 2025
Ownership: Direct
Footnotes: F1

APRE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 602
Date: 10 Dec 2025
Ownership: By Spouse
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APRE transaction Derivative

Common Warrant

Purchase

Transaction value
Shares: +21,459
Change %
Price
Shares after: 21,459
Date: 10 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 21,459
Exercise price: $1.04
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

On December 8, 2025, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on December 10, 2025 an aggregate of 21,459 shares of the Issuer's common stock ("Shares") at a purchase price of $1.165. The Reporting Person also received accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 21,459 Shares.

Footnote F2

The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

Footnote F3

The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise.

Footnote F4

The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the fifth year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144.